BioNexus Gene Lab Corp. (BGLC) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value (m); Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | (m) | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 947.98K USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | (m) | Accounts Payable, Current |
| Total deferred revenue | (m) | Deferred Revenue |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | Deferred Revenue |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) | Deferred Revenue |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $146.03K |
| Finance lease obligations | $52.56K |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | $947.98K | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | $946.88K | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | $637.86K | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | $804.97K | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $1.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.18M | (m) | (m) | (m) | $1.71M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.50M | (m) | (m) | (m) | $2.11M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.03M | (m) | (m) | (m) | $1.61M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $954.78K | (m) | (m) | (m) | $1.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.43M | (m) | (m) | (m) | $1.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.40M | (m) | (m) | (m) | $1.74M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.57M | (m) | (m) | (m) | $1.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.82M | (m) | (m) | (m) | $1.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.49M | (m) | (m) | (m) | $1.63M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.86M | $0.00 | (m) | (m) | $2.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.28M | $0.00 | (m) | (m) | $1.37M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.42M | $0.00 | (m) | (m) | $1.55M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.83M | $0.00 | (m) | (m) | $2.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $77.28K | (m) | (m) | $2.39M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $2.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $2.63M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $3.11M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $3.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $81.63K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $90.56K | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $94.18K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $108.87K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $80.63K | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $123.30K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $129.56K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $130.31K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |